Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases (original) (raw)

• Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nature Rev. Drug Discov. 6, 273–286 (2007).
  Article CAS Google Scholar
• Carmeliet, P. Angiogenesis in health and disease. Nature Med. 9, 653–660 (2003).
  Article CAS PubMed Google Scholar
• Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Med. 7, 987–989 (2001).
  Article CAS PubMed Google Scholar
• Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58–62 (2005).
  Article CAS PubMed Google Scholar
• Baluk, P., Hashizume, H. & McDonald, D. M. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 15, 102–111 (2005).
  Article CAS PubMed Google Scholar
• Nagy, J. A., Chang, S. H., Shih, S. C., Dvorak, A. M. & Dvorak, H. F. Heterogeneity of the tumor vasculature. Semin. Thromb. Hemost. 36, 321–331 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–1186 (1971).
  Article CAS PubMed Google Scholar
• Crawford, Y. & Ferrara, N. VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res. 335, 261–269 (2009).
  Article CAS PubMed Google Scholar
• Ferrara, N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev. 21, 21–26 (2010).
  Article CAS PubMed Google Scholar
• Paez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220–231 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Bergers, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nature Rev. Cancer 8, 592–603 (2008).
  Article CAS Google Scholar
• Ebos, J. M. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232–239 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Padera, T. P. et al. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol. Cancer Ther. 7, 2272–2279 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Miles, D. et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J. Clin. Oncol. 29, 83–88 (2010).
  Article CAS PubMed Google Scholar
• Yuan, F. et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl Acad. Sci. USA 93, 14765–14770 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Tong, R. T. et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64, 3731–3736 (2004).
  Article CAS PubMed Google Scholar
• Winkler, F. et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553–563 (2004).
  CAS PubMed Google Scholar
• Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932–936 (2005).
  Article CAS PubMed Google Scholar
• Jain, R. K. et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc. Natl Acad. Sci. USA 95, 10820–10825 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D. & Jain, R. K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416, 279–280 (2002).
  Article CAS PubMed Google Scholar
• Mazzone, M. et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136, 839–851 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Hamzah, J. et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453, 410–414 (2008).
  Article CAS PubMed Google Scholar
• Stockmann, C. et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456, 814–818 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Jain, R. K. Determinants of tumor blood flow: a review. Cancer Res. 48, 2641–2658 (1988).
  CAS PubMed Google Scholar
• Pettersson, A. et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab. Invest. 80, 99–115 (2000).
  Article CAS PubMed Google Scholar
• Fukumura, D., Duda, D. G., Munn, L. L. & Jain, R. K. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation 17, 206–225 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Jain, R. K. & Styllanopoulos, T. Delivering nanomedicine to solid tumors. Nature Rev. Clin. Oncol. 7, 653–664 (2010).
  Article CAS Google Scholar
• Baluk, P., Morikawa, S., Haskell, A., Mancuso, M. & McDonald, D. M. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 163, 1801–1815 (2003).
  Article PubMed PubMed Central Google Scholar
• Morikawa, S. et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 160, 985–1000 (2002).
  Article PubMed PubMed Central Google Scholar
• Ozawa, M. G. et al. Angiogenesis with pericyte abnormalities in a transgenic model of prostate carcinoma. Cancer 104, 2104–2115 (2005).
  Article CAS PubMed Google Scholar
• Van de Veire, S. et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 141, 178–190 (2010).
  Article CAS PubMed Google Scholar
• Hagendoorn, J. et al. Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res. 66, 3360–3364 (2006).
  Article CAS PubMed Google Scholar
• Kim, P. et al. In vivo wide-area cellular imaging by side-view endomicroscopy. Nature Methods 7, 303–305 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Less, J. R., Posner, M. C., Skalak, T. C., Wolmark, N. & Jain, R. K. Geometric resistance and microvascular network architecture of human colorectal carcinoma. Microcirculation 4, 25–33 (1997).
  Article CAS PubMed Google Scholar
• Batchelor, T. T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83–95 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med. 10, 145–147 (2004).
  Article CAS PubMed Google Scholar
• Rocha, S. F. & Adams, R. H. Molecular differentiation and specialization of vascular beds. Angiogenesis 12, 139–147 (2009).
  Article CAS PubMed Google Scholar
• Hobbs, S. K. et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA 95, 4607–4612 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Potenta, S., Zeisberg, E. & Kalluri, R. The role of endothelial-to-mesenchymal transition in cancer progression. Br. J. Cancer 99, 1375–1379 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Langenkamp, E. & Molema, G. Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer. Cell Tissue Res. 335, 205–222 (2009).
  Article CAS PubMed Google Scholar
• Yang, Z. F. & Poon, R. T. Vascular changes in hepatocellular carcinoma. Anat. Rec. (Hoboken) 291, 721–734 (2008).
  Article CAS Google Scholar
• Zhu, A. X., Duda, D. G., Sahani, D. V. & Jain, R. K. HCC and angiogenesis: possible targets and future directions. Nature Rev. Clin. Oncol. 8 Mar 2011 (doi:10.1038/nrclinonc.2011.30).
• Pries, A. R., Hopfner, M., le Noble, F., Dewhirst, M. W. & Secomb, T. W. The shunt problem: control of functional shunting in normal and tumour vasculature. Nature Rev. Cancer 10, 587–593 (2010).
  Article CAS Google Scholar
• Diaz-Flores, L. et al. Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histol. Histopathol. 24, 909–969 (2009).
  CAS PubMed Google Scholar
• Raza, A., Franklin, M. J. & Dudek, A. Z. Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am. J. Hematol. 85, 593–598 (2010).
  Article CAS PubMed Google Scholar
• Gerhardt, H. & Semb, H. Pericytes: gatekeepers in tumour cell metastasis? J. Mol. Med. 86, 135–144 (2008).
  Article PubMed Google Scholar
• Eble, J. A. & Niland, S. The extracellular matrix of blood vessels. Curr. Pharm. Des. 15, 1385–1400 (2009).
  Article CAS PubMed Google Scholar
• Boucher, Y. & Jain, R. K. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res. 52, 5110–5114 (1992).
  CAS PubMed Google Scholar
• Moeller, B. J., Richardson, R. A. & Dewhirst, M. W. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 26, 241–248 (2007).
  Article CAS PubMed Google Scholar
• Padera, T. P. et al. Pathology: cancer cells compress intratumour vessels. Nature 427, 695 (2004).
  Article CAS PubMed Google Scholar
• Dewhirst, M. W. Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat. Res. 172, 653–665 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Rey, S. & Semenza, G. L. Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovasc. Res. 86, 236–242 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Cardone, R. A., Casavola, V. & Reshkin, S. J. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nature Rev. Cancer 5, 786–795 (2005).
  Article CAS Google Scholar
• Hunt, T. K., Aslam, R., Hussain, Z. & Beckert, S. Lactate, with oxygen, incites angiogenesis. Adv. Exp. Med. Biol. 614, 73–80 (2008).
  Article CAS PubMed Google Scholar
• Kienast, Y. et al. Real-time imaging reveals the single steps of brain metastasis formation. Nature Med. 16, 116–122 (2010).
  Article CAS PubMed Google Scholar
• Sullivan, R. & Graham, C. H. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev. 26, 319–331 (2007).
  Article CAS PubMed Google Scholar
• Lunt, S. J., Chaudary, N. & Hill, R. P. The tumor microenvironment and metastatic disease. Clin. Exp. Metastasis 26, 19–34 (2009).
  Article PubMed Google Scholar
• Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871–890 (2009).
  Article CAS PubMed Google Scholar
• Graeber, T. G. et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88–91 (1996).
  Article CAS PubMed Google Scholar
• Nizet, V. & Johnson, R. S. Interdependence of hypoxic and innate immune responses. Nature Rev. Immunol. 9, 609–617 (2009).
  Article CAS Google Scholar
• Chung, A. S., Lee, J. & Ferrara, N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nature Rev. Cancer 10, 505–514 (2010).
  Article CAS Google Scholar
• Nagy, J. A., Dvorak, A. M. & Dvorak, H. F. VEGF-A and the induction of pathological angiogenesis. Annu. Rev. Pathol. 2, 251–275 (2007).
  Article CAS PubMed Google Scholar
• Jain, R. K. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nature Rev. Cancer 8, 309–316 (2008).
  Article CAS Google Scholar
• Baffert, F. et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am. J. Physiol. Heart Circ. Physiol. 290, H547–H559 (2006).
  Article CAS PubMed Google Scholar
• Kamoun, W. S. et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J. Clin. Oncol. 27, 2542–2552 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Greenberg, J. I. et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456, 809–813 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Abramovitch, R., Dafni, H., Smouha, E., Benjamin, L. E. & Neeman, M. In vivo prediction of vascular susceptibility to vascular endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Res. 59, 5012–5016 (1999).
  CAS PubMed Google Scholar
• Hedlund, E. M., Hosaka, K., Zhong, Z., Cao, R. & Cao, Y. Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature. Proc. Natl Acad. Sci. USA 106, 17505–17510 (2009).
  Article PubMed PubMed Central Google Scholar
• Fischer, C., Mazzone, M., Jonckx, B. & Carmeliet, P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nature Rev. Cancer 8, 942–956 (2008).
  Article CAS Google Scholar
• Vosseler, S., Mirancea, N., Bohlen, P., Mueller, M. M. & Fusenig, N. E. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res. 65, 1294–1305 (2005).
  Article CAS PubMed Google Scholar
• Dickson, P. V. et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin. Cancer Res. 13, 3942–3950 (2007).
  Article CAS PubMed Google Scholar
• Tailor, T. D. et al. Effect of pazopanib on tumor microenvironment and liposome delivery. Mol. Cancer Ther. 9, 1798–1808 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Myers, A. L., Williams, R. F., Ng, C. Y., Hartwich, J. E. & Davidoff, A. M. Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation. J. Pediatr. Surg. 45, 1080–1085 (2010).
  Article PubMed PubMed Central Google Scholar
• Franco, M. et al. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res. 66, 3639–3648 (2006).
  Article CAS PubMed Google Scholar
• Aragones, J., Fraisl, P., Baes, M. & Carmeliet, P. Oxygen sensors at the crossroad of metabolism. Cell. Metab. 9, 11–22 (2009).
  Article CAS PubMed Google Scholar
• Majmundar, A. J., Wong, W. J. & Simon, M. C. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 40, 294–309 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• De Bock, K., De Smet, F., Leite De Oliveira, R., Anthonis, K. & Carmeliet, P. Endothelial oxygen sensors regulate tumor vessel abnormalization by instructing phalanx endothelial cells. J. Mol. Med. 87, 561–569 (2009).
  Article CAS PubMed Google Scholar
• Jain, R. K. Molecular regulation of vessel maturation. Nature Med. 9, 685–693 (2003).
  Article CAS PubMed Google Scholar
• Hellberg, C., Ostman, A. & Heldin, C. H. PDGF and vessel maturation. Recent Results Cancer Res. 180, 103–114 (2010).
  Article CAS PubMed Google Scholar
• Gaengel, K., Genove, G., Armulik, A. & Betsholtz, C. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 29, 630–638 (2009).
  Article CAS PubMed Google Scholar
• Abramsson, A., Lindblom, P. & Betsholtz, C. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J. Clin. Invest. 112, 1142–1151 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Huang, F. J. et al. Pericyte deficiencies lead to aberrant tumor vascularizaton in the brain of the NG2 null mouse. Dev. Biol. 344, 1035–1046 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Yonenaga, Y. et al. Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. Oncology 69, 159–166 (2005).
  Article PubMed Google Scholar
• Jayson, G. C. et al. Blockade of platelet-derived growth factor receptor-β by CDP860, a humanized, PEGylated di-Fab′, leads to fluid accumulation and is associated with increased tumor vascularized volume. J. Clin. Oncol. 23, 973–981 (2005).
  Article CAS PubMed Google Scholar
• Liu, J. et al. PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer. Clin. Cancer Res. 1 Apr 2011 (doi:10.1158/1078-0432.CCR-10-2456).
• Nisancioglu, M. H. et al. Generation and characterization of Rgs5 mutant mice. Mol. Cell Biol. 28, 2324–2331 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Augustin, H. G., Koh, G. Y., Thurston, G. & Alitalo, K. Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system. Nature Rev. Mol. Cell Biol. 10, 165–177 (2009).
  Article CAS Google Scholar
• Thurston, G. et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286, 2511–2514 (1999).
  Article CAS PubMed Google Scholar
• Stoeltzing, O. et al. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res. 63, 3370–3377 (2003).
  CAS PubMed Google Scholar
• Saharinen, P. et al. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell–cell and cell–matrix contacts. Nature Cell Biol. 10, 527–537 (2008).
  Article CAS PubMed Google Scholar
• Chae, S. S. et al. Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin. Cancer Res. 16, 3618–3627 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Falcon, B. L. et al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am. J. Pathol. 175, 2159–2170 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Nasarre, P. et al. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res. 69, 1324–1333 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Koh, Y. J. et al. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 18, 171–184 (2010).
  Article CAS PubMed Google Scholar
• Kashiwagi, S. et al. Perivascular nitric oxide gradients normalize tumor vasculature. Nature Med. 14, 255–257 (2008).
  Article CAS PubMed Google Scholar
• Qian, B. Z. & Pollard, J. W. Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39–51 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Carmeliet, P. et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nature Med. 7, 575–583 (2001).
  Article CAS PubMed Google Scholar
• Rolny, C. et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19, 31–44 (2011).
  Article CAS PubMed Google Scholar
• Bais, C. et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 141, 166–177 (2010).
  Article CAS PubMed Google Scholar
• Gullino, P. M. Consideration on blood supply and fluid exchange in tumors. Prog. Clin. Biol. Res. 107, 1–20 (1982).
  CAS PubMed Google Scholar
• Bullitt, E. et al. Abnormal vessel tortuosity as a marker of treatment response of malignant gliomas: preliminary report. Technol. Cancer Res. Treat. 3, 577–584 (2004).
  Article PubMed Google Scholar
• Wagemakers, M. et al. Tumor vessel biology in pediatric intracranial ependymoma. J. Neurosurg. Pediatr. 5, 335–341 (2010).
  Article PubMed Google Scholar
• Willett, C. G. et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J. Clin. Oncol. 27, 3020–3026 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Willett, C. G. et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J. Clin. Oncol. 23, 8136–8139 (2005).
  Article PubMed Google Scholar
• Batchelor, T. T. et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 28, 2817–2823 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Sorensen, A. G. et al. A “vascular normalization index” as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 69, 5296–5300 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Sorensen, A. G., Batchelor, T. T., Wen, P. Y., Zhang, W. T. & Jain, R. K. Response criteria for glioma. Nature Clin. Pract. Oncol. 5, 634–644 (2008).
  Article Google Scholar
• Claes, A. et al. Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol. Cancer Ther. 7, 71–78 (2008).
  Article CAS PubMed Google Scholar
• Zhu, A. X. et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J. Clin. Oncol. 27, 3027–3035 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Duda, D. G. et al. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist 15, 577–583 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Wildiers, H. et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br. J. Cancer 88, 1979–1986 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Shrimali, R. K. et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70, 6171–6180 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Van Steenkiste, C. et al. Role of placental growth factor in mesenteric neoangiogenesis in a mouse model of portal hypertension. Gastroenterology 137, 2112–2124 (2009).
  Article CAS PubMed Google Scholar
• Plotkin, S. R. et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N. Engl. J. Med. 361, 358–367 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Jain, R. K., Finn, A. V., Kolodgie, F. D., Gold, H. K. & Virmani, R. Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization. Nature Clin. Pract. Cardiovasc. Med. 4, 491–502 (2007).
  Article CAS Google Scholar
• Gupta, R., Tongers, J. & Losordo, D. W. Human studies of angiogenic gene therapy. Circ. Res. 105, 724–736 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Stantz, K. M., Cao, M., Cao, N., Liang, Y. & Miller, K. D. Monitoring the longitudinal intra-tumor physiological impulse response to VEGFR2 blockade in breast tumors using DCE-CT. Mol. Imaging Biol. 19 Oct 2010 (doi:10.1007/s11307-010-044-7).
• O'Connor, J. P. et al. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin. Cancer Res. 15, 6674–6682 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Ansiaux, R. et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin. Cancer Res. 11, 743–750 (2005).
  CAS PubMed Google Scholar
• Zhou, Q., Guo, P. & Gallo, J. M. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin. Cancer Res. 14, 1540–1549 (2008).
  Article PubMed Google Scholar
• Dings, R. P. et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin. Cancer Res. 13, 3395–3402 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Eichhorn, M. E. et al. Contrast enhanced MRI and intravital fluorescence microscopy indicate improved tumor microcirculation in highly vascularized melanomas upon short-term anti-VEGFR treatment. Cancer Biol. Ther. 7, 1006–1013 (2008).
  Article CAS PubMed Google Scholar
• Maione, F. et al. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J. Clin. Invest. 119, 3356–3372 (2009).
  CAS PubMed PubMed Central Google Scholar
• McGee, M. C. et al. Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 76, 1537–1545 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Kamoun, W. S. et al. Simultaneous measurement of RBC velocity, flux, hematocrit and shear rate in vascular networks. Nature Methods 7, 655–660 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Heishi, T. et al. Restoration of peri-vascular nitric oxide gradient radio-sensitizes murine breast cancers via vascular normalization. American Association for Cancer Research [online], (2011).
  Google Scholar